Frontiers in Immunology (Jun 2021)
Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection
- Irene Ramos,
- Carl Goforth,
- Alessandra Soares-Schanoski,
- Dawn L. Weir,
- Emily C. Samuels,
- Emily C. Samuels,
- Shreshta Phogat,
- Shreshta Phogat,
- Michelle Meyer,
- Michelle Meyer,
- Kai Huang,
- Kai Huang,
- Colette A. Pietzsch,
- Colette A. Pietzsch,
- Yongchao Ge,
- Brian L. Pike,
- James Regeimbal,
- Mark P. Simons,
- Michael S. Termini,
- Sindhu Vangeti,
- Nada Marjanovic,
- Stephen Lizewski,
- Rhonda Lizewski,
- Mary-Catherine George,
- Venugopalan D. Nair,
- Gregory R. Smith,
- Weiguang Mao,
- Maria Chikina,
- Christopher C. Broder,
- Eric D. Laing,
- Alexander Bukreyev,
- Alexander Bukreyev,
- Alexander Bukreyev,
- Stuart C. Sealfon,
- Andrew G. Letizia
Affiliations
- Irene Ramos
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Carl Goforth
- Naval Medical Research Center, Silver Spring, MD, United States
- Alessandra Soares-Schanoski
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Dawn L. Weir
- Naval Medical Research Center, Silver Spring, MD, United States
- Emily C. Samuels
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Emily C. Samuels
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States
- Shreshta Phogat
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Shreshta Phogat
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States
- Michelle Meyer
- Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States
- Michelle Meyer
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States
- Kai Huang
- Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States
- Kai Huang
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States
- Colette A. Pietzsch
- Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States
- Colette A. Pietzsch
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States
- Yongchao Ge
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Brian L. Pike
- Naval Medical Research Center, Silver Spring, MD, United States
- James Regeimbal
- Naval Medical Research Center, Silver Spring, MD, United States
- Mark P. Simons
- Naval Medical Research Center, Silver Spring, MD, United States
- Michael S. Termini
- Directorate for Public Health, Navy Medicine Readiness and Training Command Beaufort, Beaufort, SC, United States
- Sindhu Vangeti
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Nada Marjanovic
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Stephen Lizewski
- Department of Parasitology, Naval Medical Research Unit 6, Lima, Peru
- Rhonda Lizewski
- Department of Bacteriology, Naval Medical Research Unit 6, Lima, Peru
- Mary-Catherine George
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Venugopalan D. Nair
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Gregory R. Smith
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Weiguang Mao
- 0Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
- Maria Chikina
- 0Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
- Christopher C. Broder
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Eric D. Laing
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Alexander Bukreyev
- Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States
- Alexander Bukreyev
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States
- Alexander Bukreyev
- 1Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States
- Stuart C. Sealfon
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- Andrew G. Letizia
- Naval Medical Research Center, Silver Spring, MD, United States
- DOI
- https://doi.org/10.3389/fimmu.2021.681586
- Journal volume & issue
-
Vol. 12
Abstract
We investigated serological responses following a SARS-CoV-2 outbreak in spring 2020 on a US Marine recruit training base. 147 participants that were isolated during an outbreak of respiratory illness were enrolled in this study, with visits approximately 6 and 10 weeks post-outbreak (PO). This cohort is comprised of young healthy adults, ages 18-26, with a high rate of asymptomatic infection or mild symptoms, and therefore differs from previously reported longitudinal studies on humoral responses to SARS-CoV-2, which often focus on more diverse age populations and worse clinical presentation. 80.9% (119/147) of the participants presented with circulating IgG antibodies against SARS-CoV-2 spike (S) receptor-binding domain (RBD) at 6 weeks PO, of whom 97.3% (111/114) remained positive, with significantly decreased levels, at 10 weeks PO. Neutralizing activity was detected in all sera from SARS-CoV-2 IgG positive participants tested (n=38) at 6 and 10 weeks PO, without significant loss between time points. IgG and IgA antibodies against SARS-CoV-2 RBD, S1, S2, and the nucleocapsid (N) protein, as well neutralization activity, were generally comparable between those participants that had asymptomatic infection or mild disease. A multiplex assay including S proteins from SARS-CoV-2 and related zoonotic and human endemic betacoronaviruses revealed a positive correlation for polyclonal cross-reactivity to S after SARS-CoV-2 infection. Overall, young adults that experienced asymptomatic or mild SARS-CoV-2 infection developed comparable humoral responses, with no decrease in neutralizing activity at least up to 10 weeks after infection.
Keywords
